Side effects happen because GLP-1 affects more than one area of the body
You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)
Choline-containing supplements: Concurrent use with the choline in this formulation may produce additive effects on liver fat metabolism
This deficiency can result from issues with the testes, known as primary hypogonadism, or from problems in the brains signaling to the testes, referred to as secondary hypogonadism
As a critical component of Phase II detoxification processes, glutathione participates in the conjugation and elimination of various endogenous and exogenous compounds
Information Collection: We collect only the information necessary to provide and improve healthcare to our patients